Alluvi, formerly BI 4744, presents a promising advance in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable results in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/